摘要
卵巢上皮性癌(EOC)是死亡率最高的妇科恶性肿瘤,因早期症状不明显且缺乏有效的筛查手段,70%以上的患者在诊断时已属于晚期(Ⅲ~Ⅳ期)。尽管随着治疗方法的改进,患者的5年无进展生存期(PFS)延长,但预后仍较差,50%~95%的患者治疗后2年内复发。人附睾蛋白4(HE4)和糖类抗原125(CA125)被广泛应用于EOC的诊断、治疗和预后的评估,但关于两者的评估效果相关文献报道较少,因此有必要对HE4和CA125评估EOC诊治效果及预后的研究进展进行综述。
Epithelial ovarian cancer(EOC)has the highest mortality rate among the gynecological malignancies.Because of its early symptoms are not obvious and lack of effective screening methods,more than 70%patients have been diagnosed at late stage(stageⅢ-Ⅳ).Although the 5-year progression-free survival(PFS)of EOC was prolonged with the improvement of treatment methods,its prognosis was still poor,and 50%-95%patients relapsed within 2 years after treatment.Human epididymis protein 4(HE4)and carbohydrate antigen 125(CA125)are widely used in the evaluation of diagnosis,treatment efficacy and prognosis of EOC,but the evaluation effect of both HE4 and CA125 is rarely reported.Therefore,it is necessary to summarize the research progress of HE4 and CA125 in evaluating the diagnosis,treatment efficacy and prognosis of EOC.
作者
童萌
孙立新
Tong Meng;Sun Lixin(Graduate School of Shanxi Medical University,Taiyuan 030001,China;Department of Gynecology 2,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China)
出处
《肿瘤研究与临床》
CAS
2019年第1期58-61,共4页
Cancer Research and Clinic
关键词
卵巢上皮性癌
人附睾蛋白4
糖类抗原125
诊断
预后
Epithelial ovarian cancer
Human epididymis protein 4
Carbohydrate antigen 125
Diagnosis
Prognosis
